Corrigendum: Comprehensive pan-cancer analysis of the prognostic and immunological roles of the METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C axis
Xiulin Jiang1† 
Lincan Duan- 1Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming, China
- 2Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China
A Corrigendum on
Comprehensive pan-cancer analysis of the prognostic and immunological roles of the METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C axis
by Jiang X, Yuan Y, Tang L, Wang J, Liu Q, Zou X and Duan L (2021). Front. Cell Dev. Biol. 9:765772. doi: 10.3389/fcell.2021.765772
In the published article, there was an error in Figure 9E as published. Due to negligence and lack of careful inspection, and this part of the sequence is very similar. Therefore, some base mapping errors occurred, the inaccurate WT sequence for SNHG1 is:UCUUUAUCUUGAGCUGUGGUA (In Figure 9E). The corrected WT sequence for SNHG1 is: AUUUUUCUACUGCUCGUGGUA. The Figure 9E caption was correct. The corrected Figure 9E appear below.
Figure 9. Analysis of upstream lncRNA of miRNA-140-3p in pan-cancer. (A) The correlation between the SNHG1 and miRNA-140-3p in LUAD analysis by Starbase. (B) The subcellular localization of SNHG1 examined by lncLocator. (C) The coding potential of SNHG1 analysis by coding the potential calculator. (D) The expression of SNHG1 in NSCLC cell lines examined by qRT-PCR assay. (E) The target sites between miRNA-140-3p and SNHG1 was predicted by Starbase. (F,G) Relative luciferase activities of wild-type (WT) and mutated (MUT) SNHG1 reporter plasmid in A549 and H1975 cells co-transfected with miR-140-3p mimics examined by luciferase reporter assay. (H,I) The expression of UBE2C after depletion of SNHG1 in NSCLC cell lines examined by qRT-PCR assay. (J) The correlation between miRNA-140-3p and UBE2C, SNHG1 in NSCLC examined by Starbase. *p < 0.05, **p < 0.01, ***p < 0.001.
In the published article, there was an error in the Materials and methods, Quantitative Real-Time PCR section: primer sequences: SNHG1-F: AGCATCCACGAGCAAGAGAC, SNHG1-R: GATGCTACTAGTGTGGCGGG.
A correction has been made to primer sequences: SNHG1-F: GCATCTCATAATCTATCCTGG, SNHG1- R:CCTAGTTTTCCTCAAACTCCT. This sentence previously stated:
“SNHG1-F: AGCATCCACGAGCAAGAGAC, SNHG1-R: GATGCTACTAGTGTGGCGGG”
The corrected sentence appears below:
“SNHG1-QPCR-F-GCATCTCATAATCTATCCTGG, SNHG1-QPCR-R-CCTAGTTTTCCTCAAACTCCT”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: epigenetics, SNHG1, miRNA-140-3p, UBE2C, pan-cancer, prognosis, immunotherapy, drug sensitivity
Citation: Jiang X, Yuan Y, Tang L, Wang J, Liu Q, Zou X and Duan L (2024) Corrigendum: Comprehensive pan-cancer analysis of the prognostic and immunological roles of the METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C axis. Front. Cell Dev. Biol. 12:1392532. doi: 10.3389/fcell.2024.1392532
Received: 27 February 2024; Accepted: 22 March 2024;
Published: 05 April 2024.
Edited and reviewed by:
Ping Wang, Tianjin Medical University, ChinaCopyright © 2024 Jiang, Yuan, Tang, Wang, Liu, Zou and Duan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lincan Duan, duanmumuhuosan@163.com
†These authors have contributed equally to this work